Abstract
The occurrence of neuroleptic malignant syndrome (NMS) was studied prospectively in two series of consecutive psychiatric in-patients (n = 223). The first group (n = 120) suffered from schizophrenia and was treated only with haloperidol. The second group (n = 103) was treated with diverse neuroleptics. All patients were on a single antipsychotic agent with no anticholinergic drug as prophylaxis. The incidence of full NMS per admission and first neuroleptic exposure was 5/223 (2.2%). Patients with bipolar affective disorder and those treated with injections were significantly over-represented in the NMS group.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Administration, Oral
-
Antipsychotic Agents / administration & dosage
-
Antipsychotic Agents / adverse effects*
-
Bipolar Disorder / drug therapy*
-
Bipolar Disorder / psychology
-
Creatine Kinase / blood
-
Female
-
Follow-Up Studies
-
Haloperidol / administration & dosage
-
Haloperidol / adverse effects
-
Hospitalization*
-
Humans
-
Injections, Intramuscular
-
Male
-
Methotrimeprazine / administration & dosage
-
Methotrimeprazine / adverse effects
-
Neuroleptic Malignant Syndrome / diagnosis
-
Neuroleptic Malignant Syndrome / etiology*
-
Neurologic Examination / drug effects
-
Perphenazine / administration & dosage
-
Perphenazine / adverse effects
-
Prospective Studies
-
Risk Factors
-
Schizophrenia / drug therapy*
-
Schizophrenic Psychology*
Substances
-
Antipsychotic Agents
-
Methotrimeprazine
-
Creatine Kinase
-
Perphenazine
-
Haloperidol